Leerink Partners Remains Bullish as Teva Pharma (TEVA) Awaits IPR Ruling
Tweet Send to a Friend
Leerink Partners reiterated an Outperform rating and $66.00 price target on Teva Pharma (NYSE: TEVA) ahead of an IPR ruling ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
